News and Trends 18 Jul 2022 Positive results for drug combination used to treat rare blood cancer Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 13 Jul 2022 The biggest European biotech investments in June 2022 Oncology and AI-guided drug discovery firms roped in the biggest biotech investments in Europe in June 2022. The leading private rounds went to companies including ImCheck Therapeutics, MiroBio and Charm Therapeutics. In June 2022, we saw bigger private biotech investments in Europe than in May. ImCheck Therapeutics took the top spot; the firm raised an […] July 13, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 12 Jul 2022 Where AI can’t go: PhoreMost’s quest to unearth protein degradation targets Advances in the AI-powered simulation of proteins are making it easier than ever to discover new drugs. Neil Torbett, CEO of PhoreMost, outlines how the firm’s protein screening technology overcomes current limitations of protein structure predictions, with big applications in the emerging field of protein degradation. Proteins are a critical component to a cell’s activities, […] July 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 New home for wet lab incubator in bid to help biotech start-ups and promote life sciences A lab to bring together the hive minds of those addressing the future challenges in healthcare, including biotech start-ups, is set to open at Discovery Park, Kent, U.K. Barclays has selected the location as the home for its latest Eagle Lab, which will open later this year. The labs are a growing national network currently at […] July 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Time Partners closes £30M venture fund to back life sciences startups Time Partners Limited has announced the final closing of its first advised fund, Time Boost Capital I LP, a £30 million ($36.6 million) genomics venture fund to provide match funding to startups graduating from Illumina Accelerator Cambridge, UK. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications […] June 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Companies unite to bolster diagnostics for cancer and liver disease Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […] June 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Roquefort Therapeutics buys UK biotech in return for shares Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares. Oncogeni develops novel patented cancer medicines, and will receive 50 million shares, worth just under £4 million ($4.9 million). Acquisition In light of the acquisition, Oncogeni co-founder Ajan Reginald will become chief executive of the group, and […] June 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […] June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2022 New treatment option available for Dravet syndrome Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. […] June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Therapeutic RNA company receives additional funding UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has successfully raised £4.6M ($5.8M) in additional seed funding. The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). Transine said the additional funds will enable it to further develop its SINEUP […] May 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments UK neuroscience company NRG Therapeutics Ltd has received a Biomedical Catalyst (BMC) award to fund preclinical development of its small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68M ($5.8M) early-stage BMC award part-funded by the government-backed agency Innovate UK will support a […] May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 ANGLE and U.S. urology group to undertake prostate cancer study ANGLE plc has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the U.S. Alongside Solaris affiliate MidLantic Urology, UK-headquartered ANGLE will initiate clinical studies aimed at detecting prostate […] May 31, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email